OSR (OSRH) versus Its Competitors Financial Contrast

OSR (NASDAQ:OSRH) is one of 89 public companies in the “UNCLASSIFIED” industry, but how does it contrast to its competitors? We will compare OSR to related companies based on the strength of its institutional ownership, analyst recommendations, dividends, valuation, risk, profitability and earnings.

Risk and Volatility

OSR has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, OSR’s competitors have a beta of -0.09, suggesting that their average share price is 109% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for OSR and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1	0	0	0	1.00
OSR Competitors	231	266	217	3	1.99

As a group, “UNCLASSIFIED” companies have a potential upside of 124.97%. Given OSR’s competitors stronger consensus rating and higher probable upside, analysts plainly believe OSR has less favorable growth aspects than its competitors.

Institutional & Insider Ownership

55.3% of OSR shares are owned by institutional investors. Comparatively, 51.0% of shares of all “UNCLASSIFIED” companies are owned by institutional investors. 60.6% of OSR shares are owned by insiders. Comparatively, 42.7% of shares of all “UNCLASSIFIED” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OSR and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OSR	N/A	-6.66%	-4.90%
OSR Competitors	0.86%	0.95%	0.80%

Valuation and Earnings

This table compares OSR and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OSR	N/A	-$2.41 million	-0.49
OSR Competitors	$42.00 million	-$18.84 million	93.13

OSR’s competitors have higher revenue, but lower earnings than OSR. OSR is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

OSR competitors beat OSR on 9 of the 13 factors compared.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.